Caris Life Sciences delivered record Q3 2026 revenue of $275.4M, up 27%, while raising full-year guidance and expanding its oncology platform into monitoring and MRD markets.
Caris Life Sciences reported total revenue of $755.2 million for the nine months ended September 30, 2026, a significant increase from $519.1 million in the prior year period. The company achieved a net income from operations of $51.5 million for the first nine months of 2026, compared to an operating loss of $43.3 million in 2025, driven primarily by growth in molecular profiling services.
Caris Life Sciences reported Q3 2026 revenue of $275.4 million, a 27% increase year-over-year, driven by strong molecular profiling clinical case volume. The company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion and reported positive net income of $15.3 million for the quarter.
Term
Q3 2026
“This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year. Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey.”